LG Chem targets ‘undruggable’ p53 with new cancer drug deal

LG Chem has doubled down on developing an innovative cancer treatment by zeroing in on undruggable targets through a license-in agreement with Frontier Medicines, a United States-based biotechnology company. According to LG Chem’s announcement Wednesday, it acquired the exclusive worldwide license to develop and commercialize Frontier Medicines’ FMC-220 outside Greater China, with the latter retaining ownership and full control in Greater China. Under the agreement, LG Chem will be responsible f

By The Korea Herald